Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eculizumab + ravulizumab
- Development stage
- Unknown
- Lead developer
- Alexion Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Soliris (eculizumab) and Ultomiris (ravulizumab) are monoclonal antibodies that target the complement protein C5. Developed by Alexion Pharmaceuticals (now part of AstraZeneca), they inhibit the cleavage of C5 into C5a and C5b, thereby preventing the formation of the terminal complement complex (C5b-9). Soliris was the first-in-class C5 inhibitor, while Ultomiris is a second-generation, long-acting formulation designed with a higher binding affinity and a longer half-life, allowing for maintenance dosing every 8 weeks compared to every 2 weeks for Soliris. They are primarily used to treat complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Both drugs are available in the US only through a restricted access program called the Ultomiris and Soliris REMS due to the risk of serious meningococcal infections.
- Brand names
- SolirisUltomiris
- Other names
- eculizumab + ravulizumab
02
Targets
C5
Beyond the preview
Go deeper on eculizumab + ravulizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eculizumab + ravulizumab.